Benitec Biopharma Inc. (NASDAQ:BNTC) Brief Update on Interests
Benitec Biopharma Inc. (NASDAQ: BNTC – Get a rating) benefited from a sharp rise in short-term interest rates in March. As of March 31, there was selling interest totaling 5,600 shares, an increase of 75.0% from the March 15 total of 3,200 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average trading volume of 25,800 shares, the day-to-cover ratio is currently 0.2 days.
An institutional investor recently raised its position in Benitec Biopharma stock. Geode Capital Management LLC increased its stake in the shares of Benitec Biopharma Inc. (NASDAQ: BNTC – Get a rating) by 55.7% in Q3, according to the company in its latest 13F filing with the Securities and Exchange Commission. The fund held 53,692 shares of the biotech company after buying an additional 19,199 shares during the quarter. Geode Capital Management LLC owned 0.66% of Benitec Biopharma worth $191,000 when it last filed with the SEC. Institutional investors hold 20.15% of the company’s shares.
NASDAQ BNTC open at $2.00 on Fridays. The stock has a market capitalization of $16.33 million, a PE ratio of -0.01 and a beta of 1.44. Benitec Biopharma has a fifty-two week minimum of $1.90 and a fifty-two week maximum of $5.86. The company has a 50-day moving average price of $2.31 and a two-hundred-day moving average price of $2.82. The company has a quick ratio of 5.11, a current ratio of 5.11 and a leverage ratio of 0.06.
Separately, HC Wainwright began covering Benitec Biopharma in a Thursday, February 17 report. They issued a “buy” rating and a price target of $10.00 for the company.
Benitec Biopharma Company Profile (Get a rating)
Benitec Biopharma Inc, a development-stage biotechnology company, focuses on the development of new genetic drugs. The company develops DNA-directed RNA interference-based therapies for chronic and life-threatening human diseases. It is developing BB-301, an adeno-associated virus-based gene therapy agent for the treatment of oculo-pharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection.
Get news and reviews for Benitec Biopharma Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Benitec Biopharma and related companies with MarketBeat.com’s FREE daily newsletter.